Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RNASEH2B loss and PARP inhibition in advanced prostate cancer

4 Jun 2024

Abstract excerpt

BACKGROUNDClinical trials have suggested antitumor activity from PARP inhibition beyond homologous recombination deficiency (HRD). RNASEH2B loss is unrelated to HRD and preclinically sensitizes to PARP inhibition. The current study reports on RNASEH2B protein loss in advanced prostate cancer and its association with RB1 protein loss, clinical outcome, and clonal dynamics during treatment with PARP inhibition in a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to PARP inhibition in cancer therapy
Share to Prostate Cancer Treatment and Research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 38833311
DOI: 10.1172/jci178278

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RNASEH2B loss and PARP inhibition in advanced prostate cancerPMID 38833311Read ↗

RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancerSemantic proximity Read ↗

RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancerSemantic proximity Read ↗

Homologous recombination deficiency and genomic alterations in advanced prostate cancer: insights for precision therapy.Semantic proximity Read ↗

PARP inhibitors in advanced prostate cancer: when to use them?Semantic proximity Read ↗

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.Semantic proximity Read ↗

Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancerSemantic proximity Read ↗

Genomic aberration based molecular signatures efficiently characterize homologous recombination deficiency in prostate cancerSemantic proximity Read ↗

PARP inhibitors for homologous recombination-deficient prostate cancer.Semantic proximity Read ↗

Alterations in BRCA2 as Determinants of Therapy Response in Prostate Cancer.Semantic proximity Read ↗

Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 functionSemantic proximity Read ↗

Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression.Semantic proximity Read ↗

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.